Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
McKinsey
Boehringer Ingelheim
Merck
Dow

Last Updated: September 25, 2022

CEQUA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Cequa patents expire, and when can generic versions of Cequa launch?

Cequa is a drug marketed by Sun Pharm and is included in one NDA. There are four patents protecting this drug.

This drug has twenty-three patent family members in thirteen countries.

The generic ingredient in CEQUA is cyclosporine. There are eighteen drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the cyclosporine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Cequa

A generic version of CEQUA was approved as cyclosporine by HIKMA on October 29th, 1999.

  Try it Free

US Patents and Regulatory Information for CEQUA

CEQUA is protected by four US patents.

Patents protecting CEQUA


Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Topical cyclosporine-containing formulations and uses thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Topical aqueous nanomicellar, ophthalmic solutions and uses thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: INCREASE TEAR PRODUCTION IN PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE).

Topical formulations and uses thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: INCREASE TEAR PRODUCTION IN PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE).

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sun Pharm CEQUA cyclosporine SOLUTION;OPHTHALMIC 210913-001 Aug 14, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Sun Pharm CEQUA cyclosporine SOLUTION;OPHTHALMIC 210913-001 Aug 14, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Sun Pharm CEQUA cyclosporine SOLUTION;OPHTHALMIC 210913-001 Aug 14, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Sun Pharm CEQUA cyclosporine SOLUTION;OPHTHALMIC 210913-001 Aug 14, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for CEQUA

See the table below for patents covering CEQUA around the world.

Country Patent Number Title Estimated Expiration
South Korea 20180117661 국소형 시클로스포린 함유 제형 및 그의 용도 See Plans and Pricing
Mexico 2018010395 FORMULACIONES TOPICAS QUE CONTIENEN CLICLOSPORINA Y USOS DE LAS MISMAS. (TOPICAL CYCLOSPORINE-CONTAINING FORMULATIONS AND USES THEREOF.) See Plans and Pricing
Mexico 2015002239 FORMULACION OFTALMICA DE LIPIDO POLIOXILO O DE ACIDO GRASO POLIOXILO Y TRATAMIENTO DE PADECIMIENTOS OCULARES. (OPHTHALMIC FORMULATION OF POLYOXYL LIPID OR POLYOXYL FATTY ACID AND TREATMENT OF OCULAR CONDITIONS.) See Plans and Pricing
Russian Federation 2019130403 ЦИКЛОСПОРИН-СОДЕРЖАЩИЕ ЛЕКАРСТВЕННЫЕ ФОРМЫ ДЛЯ НАРУЖНОГО ПРИМЕНЕНИЯ И ИХ ПРИМЕНЕНИЯ See Plans and Pricing
World Intellectual Property Organization (WIPO) 2017151657 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for CEQUA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2049079 LUC00006 Luxembourg See Plans and Pricing PRODUCT NAME: CYCLOSPORINE (GOUTTES OCULAIRES SOUS FORME D'EMULSION); AUTHORISATION NUMBER AND DATE: EU/1/15/990 20150323
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
Harvard Business School
Boehringer Ingelheim
Moodys
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.